Illinois Advances Drug‑Price Board
Illinois lawmakers moved a bill forward to create a prescription drug affordability board that could set price limits on selected medicines — part of a growing U.S. trend toward state‑level drug pricing oversight. ( )
House Bill 1443 — the Health Care Availability and Access Board Act — was advanced out of the House Health Care Availability & Accessibility Committee on March 24, 2026 in an 8–4, party-line vote. (legiscan.com) The draft text empowers the board to perform affordability reviews and to impose “upper payment limits” on prescription products that meet statutory triggers, with analyses citing thresholds that would capture certain brand-name specialty drugs priced at roughly above $60,000 per year. (billtrack50.com) Legislative language in the bill requires the board to adopt the federal Medicare Maximum Fair Price as the upper payment limit for drugs that have an MFP and bars the board from setting a different cap, and it states any enactment would take effect 180 days after becoming law. (legiscan.com) Sponsors and backers named in coverage include Sen. Graciela Guzmán and Rep. Nabeela Syed, with the measure contained in House Bill 1443 and a companion Senate bill (Senate Bill 66), and advocacy groups such as Citizen Action/Illinois mounting public rallies earlier this year. (capitolcitynow.com) Lawmakers and stakeholders raised regulatory and legal concerns during committee testimony — noting prior industry pushback when similar proposals stalled in 2019 and questioning implementation details that proponents say will be amended before a floor vote. (capitolcitynow.com) The proposal follows 2025 state reforms targeting pharmacy benefit managers: Gov. J.B. Pritzker signed the Prescription Drug Affordability Act (H.B. 1697) on July 1, 2025, a law that imposed PBM transparency and reporting rules and created a $25 million annual grant program to support independent pharmacies. (gov-pritzker-newsroom.prezly.com)
